Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Screening of ROS1 Rearrangements in Lung Adenocarcinoma by Immunohistochemistry and Comparison with ALK Rearrangements

24 Jul 2014

Abstract excerpt

ROS1 rearrangement is a predictive biomarker for response to the tyrosine kinase inhibitor, crizotinib. We investigated the usefulness of ROS1 immunohistochemistry (IHC) for the detection of patients who harbor ROS1 rearrangements in two separate cohorts. We also compared ROS1 IHC with ALK IHC in terms of diagnostic performance to predict each gene rearrangement. In a retrospective cohort, IHC was performed in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cholangiocarcinoma and Gallbladder Cancer Studies
Share to Lung Cancer Research Studies
Share to Lung Cancer Treatments and Mutations

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 25058391
DOI: 10.1371/journal.pone.0103333

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Screening of ROS1 Rearrangements in Lung Adenocarcinoma by Immunohistochemistry and Comparison with ALK RearrangementsPMID 25058391Read ↗

ROS1 immunohistochemistry for detection of ROS1-rearranged lung adenocarcinomas.Semantic proximity Read ↗

ROS1 immunohistochemistry among major genotypes of non-small-cell lung cancer.Semantic proximity Read ↗

<i>ROS1</i> Rearrangements Define a Unique Molecular Class of Lung CancersSemantic proximity Read ↗

Testing for ROS1 in non-small cell lung cancer: a review with recommendationsSemantic proximity Read ↗

Crizotinib for the treatment of ALK-rearranged non-small cell lung cancer: a success story to usher in the second decade of molecular targeted therapy in oncology.Semantic proximity Read ↗

Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort.Semantic proximity Read ↗

Concurrent ROS1 gene rearrangement and KRAS mutation in lung adenocarcinoma: A case report and literature review.Semantic proximity Read ↗

The frequency and impact of ROS1 rearrangement on clinical outcomes in never smokers with lung adenocarcinoma.Semantic proximity Read ↗

Deepening the Knowledge of ROS1 Rearrangements in Non-Small Cell Lung Cancer: Diagnosis, Treatment, Resistance and Concomitant AlterationsSemantic proximity Read ↗

<i><scp>ROS</scp>1</i> expression and translocations in non‐small‐cell lung cancer: clinicopathological analysis of 1478 casesSemantic proximity Read ↗

High Prevalence of Concomitant Oncogene Mutations in Prospectively Identified Patients with ROS1-Positive Metastatic Lung Cancer.Semantic proximity Read ↗

A genomic and clinicopathological study of non-small-cell lung cancers with discordant ROS1 gene status by fluorescence in-situ hybridisation and immunohistochemical analysis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.